Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin effects on innate immunity
NCT03459794Phase 1Completed
- Sponsor
- University of Georgia
- Start
- Feb 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CHILD-IVITAB in onchocerciasis and filariasis (2 arms), sponsored by University of Georgia. Primary endpoints: The Number of Cytokines Showing Statistically Significant Changes From Pre-treatment Levels at 24 hours and Number of Transcripts in PBMC With Statistically Significant Changes From Pre-treatment Levels at 24 hours. Started Feb 2018; status: completed.
02
Drugs
CHILD-IVITAB
03
Conditions
onchocerciasisfilariasis
Beyond the preview
Go deeper on NCT03459794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03459794.